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Abstract
Background: To investigate the efficacy of different probiotic strains, their combinations and forms (alive or
lyophilized) in nonalcoholic fatty liver disease (NAFLD) prevention.
Methods: In this study, 70 rats have been used divided into 7 groups of 10 animals in each: I – intact rats, II-VII –
rats with monosodium glutamate (MSG)-induced NAFLD. Rats with NAFLD were untreated (group II, MSG-obesity
group) and treated with probiotics (groups III–VII). In order to develop NAFLD, newborn rats of groups II–VII were
injected with a solution of monosodium glutamate (MSG) (4 mg/g) subcutaneously (s.c.) at 2nd,4th, 6th, 8th,10th
postnatal day. The groups III–V received lyophilized monoprobiotics B. animalis VKL, B. animalis VKB, L.casei IMVB-
7280, respectively. The group VI received 2.5 ml/kg of an aqueous solution of a mixture of the three probiotic
strains (2:1:1 Lactobacillus casei IMVB-7280, Bifidobacterium animalis VKL, Bifidobacterium animalis VKB) at a dose of
50 mg/kg (5 × 109 CFU/kg) (g) (intragastrically). The group VII was treated with multiprobiotic “Symbiter” containing
biomass of 14 alive probiotic strains (Lactobacillus + Lactococcus (6 × 1010 CFU/g), Bifidobacterium (1 × 1010/g),
Propionibacterium (3 × 1010/g), Acetobacter (1 × 106/g)) at a dose of 140 mg/kg (1.4 × 1010 CFU/kg). The treatment
with probiotics was started at the age of 1 month. There were 3 courses of treatment, each included 2-week
administration and 2-week break. All parameters were measured in 4-month aged rats.
Results: Introduction of MSG during the neonatal period leads to the NAFLD development in the 4-months old
rats. For steatosis degree there was no significant difference between MSG-obesity group and lyophilized
monocomponent probiotics groups (III–V). The highest manifestation of steatosis was observed for B. animalis VKL
group (2.0 ± 0.25) as compared to B. animalis VKB (1.70 ± 0.21) and L. casei IMVB-7280 (1.80 ± 0.20). The steatosis
score changes between all monoprobiotics groups (III–V) were insignificant. Administration from birth of both
alive (VII) and lyophilized (VI) probiotic mixture lead to a significant decrease by 69.5 % (p < 0.001) and 43.5 %
(p < 0.025) of steatosis score respectively as compared to the MSG-obesity group (2.3 ± 0.21 %). For both alive
and lyophilized probiotic mixtures, reduction of lobular inflammation was observed. These histological data
were confirmed by the significant decrease of total lipids and triglycerides content in the liver approximately by
22–25 % in groups treated with probiotic mixtures (VI, VII) compared to the MSG-obesity group.
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Conclusion: We established failure of NAFLD prevention with lyophilized monoprobiotic strains and the efficacy of
probiotic mixture with the preference of alive probiotic strains.
Keywords: NAFLD, Prevention, Obesity, Lyophilized and alive probiotic strains, Monoprobiotic, Multistrain probiotics
Background
Non-alcoholic fatty liver disease (NAFLD) ranges from
simple steatosis to non-alcoholic steatohepatitis (NASH)
that can have different degrees of fibrosis and progress
to liver cirrhosis and hepatocellular carcinoma [1].
NAFLD that is associated with obesity and type 2 dia-
betes has a prevalence of 15–20 % in the general popula-
tion and 76–90 % in the obese [2]. NAFLD is currently a
leading cause of chronic liver disease [3, 4], which has
resulted in significant health concerns such as morbidity,
mortality, and liver transplants [5].
According to Day’s two-hit model of NAFLD patho-
genesis insulin resistance as the first hit, causes lipid ac-
cumulation in hepatocytes and leads to the development
of fatty liver. The second hit includes cellular insults
such as oxidative stress and lipid oxidation, which dam-
ages the liver cells and triggers an inflammatory process
that leads to pathological changes in hepatocytes that re-
sult in NASH [6]. Recent studies present a clear evi-
dence that gut microbiota are strongly implicated in
NAFLD pathogenesis and progression through several
mechanisms [7].
The underlying mechanisms, which link altered gut
microbiota composition to NAFLD are modulation of
dietary choline metabolism [8] and production of en-
dogenous ethanol [9], increased gut permeability [10]
with subsequent endotoxemia and metabolic low-grade
inflammation [11], increased energy harvest from the
diet [12] and impaired short-chain fatty acids synthesis
[13], decreased absorbtion of vitamins and biologically
active compounds [12], altered bile acids metabolism,
and FXR/TGR5 signaling [14]. Prebiotics and probiotics
have physiologic functions that contribute to the health
of gut microbiota and/or restoration of microflora,
maintenance of a healthy body weight and control of
factors associated with NAFLD through the various
above mentioned pathways [15].
In our previous work, we have shown that periodic
treatment with multiprobiotic containing biomass of 14
alive strains (Lactobacillus, Lactococcus, Bifidobacterium,
Propionibacterium, Acetobacter) prevents, at least par-
tially, the MSG-induced obesity [16] and NAFLD devel-
opment [17]. However the question regarding the
efficacy of different probiotic strains, their combination
and form (alive or lyophilized) in the management of




This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health
and the general ethical principles of animal experiments,
approved by the First National Congress on Bioethics
Ukraine (September 2001). The protocol was approved
by the Committee on the Ethics of Animal Experiments
of the Taras Shevchenko National University of Kyiv
(Protocol number: 10/2014). The rats were kept in col-
lective cages under controlled conditions of temperature
(22 ± 3 °C), light (12 h light/dark cycle) and relative hu-
midity (60 ± 5 %). The animals were fed laboratory chow
(PurinaW) and tap water ad libitum.
Experiment design
The study included 70 male Wistar rats divided into 7
groups, of 10 animals in each (Fig. 1). Newborns rats of
the control group (I) were administered with saline sub-
cutaneously (s.c.) in the volume of 8 μl/g at 2nd, 4th,
6th, 8th and 10th postnatal days. Newborns rats of
groups II–VII were injected with monosodium glutam-
ate solution (MSG) (4.0 mg/g of body weight) s.c. at
2nd, 4th, 6th, 8th and 10th postnatal days [18]. Neonatal
administration of MSG causes the significant accumula-
tion of fat in the abdomen of the adult rats. This hap-
pens because of the neurotoxicity effects on the arcuate
and ventromedial nuclei of the hypothalamus [19]. In
our previous work, we have shown the development of
NAFLD under conditions of the severe visceral obesity
induced by MSG [17]. Thus, the obtained results con-
firmed the validity of the usage of MSG for NAFLD
development.
The groups III–VII were treated with probiotics.
The groups III–V received lyophilized monoprobiotics
B. animalis VKL, B. animalis VKB, L. casei IMVB-
7280 respectively. The group VI received the mix of these
three probiotic strains. The group VII was treated with
multiprobiotic “Symbiter” which was supplied by Scientific
and Production Company “O.D. Prolisok”. It contains of
14 alive probiotic strains of Lactobacillus + Lactococcus
(6 × 1010 CFU/g), Bifidobacterium (1 × 1010/g), Propioni-
bacterium (3 × 1010/g), Acetobacter (1 × 106/g) genera.
Administration was started at the end of the 4th week
after birth and continued intermittently by alternating a
2-week course and 2 weeks intervals of nontreatment.
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Within 4 months after birth rats were on a normal diet.
All parameters were measured in 4-months old rats.
Sample collection and blood biochemistry analysis
Rats of all groups were fasted for approximately 12 h
prior sacrifice. Rats were sacrificed by cervical disloca-
tion under urethane anesthesia. Blood was drawn from
the apex of the cardiac ventricle and few blood drops
were collected into a microcentrifuge tube containing a
mixture of NaF and EDTA at a 2:1 (w/w) ratio. Blood
sample was collected into a sterile tube and centrifuged
at 3500 rpm (2260 g) for 15 min. After centrifugation
serum supernatant for further analysis was aliquoted
into microcentrifuge tubes and stored at −80 °C. Biliru-
bin, activity of alanine and aspartate aminotransferase in
serum were determined by the standard biochemical
methods.
Liver histology assessment
For histological analysis liver tissue samples from both
the right and left hepatic lobes were taken (sample size
0.5 × 0.5 cm). After fixation for 24 h in a liquid Buena,
liver fragments were dehydrated in alcohol of increasing
concentrations (from 70 to 96 °), embedded in paraffin
and then cut with a thickness of 5–6 microns and
stained with hematoxylin-eosin. A pathologist blinded to
group distributions performed the histological analyses
of slides using light microscopy («Olympus», Japan). To
assess morphological changes in the liver we used NAS
(NAFLD activity score), which includes histological fea-
tures and has been defined as unweighted sum of scores
for steatosis (0–3), lobular inflammation (0–3) and bal-
looning (0–2). Acording to NAS scores ≥5 are diagnosed
as non-alcoholic steatohepatitis (NASH), and cases with
a NAS <3 are mentioned as not NASH [20]. Lipid ex-
traction from the liver was performed according to Folch
et al. [21].
Statistical analysis
Statistical analysis was performed with the SPSS-20
software. All data in this study were expressed as
means ± standard error of the mean (M ± SEM) or %.
Fig. 1 Experiment design















Total bilirubin, umol/l 12.9 ± 0.73 12.6 ± 0.58 13.6 ± 0.68 12.5 ± 0.3 13.3 ± 0.63 12.4 ± 0.47 13.4 ± 0.63
Indirect bilirubin, umol/l 8.3 ± 0.55 8.2 ± 0.35 8.6 ± 0.47 8.2 ± 0.29 8.5 ± 0.5 8.3 ± 0.33 8.3 ± 0.53
Direct bilirubin, mmol/l 4.6 ± 0.33 4.4 ± 0.3 5.0 ± 0.29 4.3 ± 0.26 4.8 ± 0.29 4.1 ± 0.27 5.1 ± 0.23
ALT, mkkat/l 0.231 ± 0.011 0.243 ± 0.015 0.230 ± 0.013 0.209 ± 0.010 0.221 ± 0.008 0.211 ± 0.014 0.212 ± 0.007
AST, mkkat/l 0.386 ± 0.007 0.397 ± 0.011 0.396 ± 0.015 0.382 ± 0.011 0.389 ± 0.014 0.373 ± 0.016 0.381 ± 0.018
Data are presented as the M ± SEM. One-way ANOVA or Kruskall-Wallis test were performed for data analysis. All differences were not significant (p > 0.05)
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Data distribution was analyzed using the Kolmogorov-
Smirnov normality test. Continuous variables with
parametric distribution were analyzed using Analysis
of Variance (ANOVA) and if the results were signifi-
cant, a post-hoc Tukeys test was performed. For data
with non-parametric distribution Kruskall-Wallis and
post-hoc Dunn’s test were conducted for multiple
comparisons. For comparisons of categorical variables
we conducted χ2 test. The difference between groups was
defined to be statistically significant when a p-value was
less than 0.05.
Results
We didn’t find any significant difference in biochemical
indicators (alanine transaminase (ALT), aspartate trans-
aminase (AST), bilirubin) of liver in blood serum be-
tween intact, MSG-obesity and MSG-probiotics group
(Table 1).
Liver histology changes, as assessed by the NAS score,
associated with the administration of different types of
probiotics are represented in Table 2. For steatosis de-
gree there was no significant difference between the
MSG-obesity group and lyophilized monocomponent
probiotics groups (III–V) (Fig. 2a-d). The highest mani-
festation of steatosis was observed for B. animalis VKL
group (2.0 ± 0.25) as compared to B. animalis VKB
(1.70 ± 0.21) and L. casei IMVB-7280 (1.80 ± 0.20).
The steatosis score changes between all monoprobio-
tics groups (III–V) were insignificant. Administration
from birth of both alive (VII) and lyophilized (VI)
probiotic mixture lead to a significant decrease by
69.5 % (p < 0.001) and 43.5 % (p = 0.025) of steatosis
score respectively as compared to the MSG-obesity
group (2.3 ± 0.21) (Fig. 3a and b).
Similar to steatosis score changes we found that
administration of both alive and lyophilized probiotic















Steatosis (0–3) 0.10 ± 0.1a 2.30 ± 0.21d 2.0 ± 0.25cd 1.70 ± 0.21cd 1.80 ± 0.20cd 1.30 ± 0.3bc 0.70 ± 0.15ab
Lobular inflammation (0–2) 0.0 ± 0.0a 1.0 ± 0.21b 0.60 ± 0.16ab 0.40 ± 0.16ab 0.40 ± 0.16ab 0.30 ± 0.15a 0.10 ± 0.1a
Ballooning degeneration (0–2) 0.0 ± 0.0a 0.20 ± 0.13a 0.10 ± 0.1a 0.10 ± 0.1a 0.10 ± 0.1a 0.0 ± 0.0a 0.0 ± 0.0a
Total NAS (0–8) 0.0 ± 0.0a 3.60 ± 0.4d 2.70 ± 0.36cd 2.2 ± 0.25c 2.30 ± 0.21c 1.60 ± 0.3bc 0.80 ± 0.2ab
Prevalence of NASH, % – 30 10 – – – –
Data are presented as the M ± SEM. One-way ANOVA with post hoc Tukeys test for multiple comparisons were performed for data analysis. a, b, c, d Values at the
same row with different superscript letters show significant differences at p < 0.05
Fig. 2 Light microscopic micrographs of the rat liver tissue stained with hematoxylin and eosin, ×400. In micrographs predominantly
microvesicular pronounced total steatosis were mainly observed. a - MSG-induced obesity group; b - B. animalis VKL group; c - B. animalis VKB
group; d - L. casei IMVB-7280 group
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mixtures from 4th week after birth lead to a significant
reduction of liver inflammation manifestation in the
adulthood period in rats when compared with litter-
mates with MSG-induced obesity. In the liver histology
sections NASH specific lesions were observed. Specific-
ally, the inflammation was mild and predominantly lobu-
lar rather than portal, with typically mixed infiltrates,
which included chronic inflammatory cell phenotypes,
such as lymphocytes, monocytes (Fig. 4a-d). Any signifi-
cant changes in lobular inflammation as assessed by
NAS score between MSG-induced obesity group and ly-
ophilized monocomponent probiotics groups (III–V)
were not found. The most prominent changes from all
lyophilized groups were described for B. animalis VKL.
Only in this group we diagnosed NASH in 10 % of ani-
mals that was significant (p = 0.026) as compared to
MSG-obesity group with 30 % of animals with NASH.
All groups were typically relative in histological presen-
tation of ballooning degeneration due to the absence of
any significant difference (p > 0.05) (Table 2).
The lowest total NAS score was observed after ad-
ministration of alive multiprobiotic group (0.8 ± 0.2)
that were insignificant in control rats and statistically
lower as compared to all monoprobiotics groups (III–V).
When used lyophilized (VI) probiotic mixture changes in
total NAS score between other treated were insignificant.
In parallel with improving of total NAS score for both
policomponent probiotic mixture, we observed a signifi-
cant decrease of total lipids and triglycerides content in
liver approximately by 22–25 % respectively as com-
pared to the MSG-obesity group (Fig. 5a and b). After
administration of lyophilized monocomponents probio-
tics (groups III–V) the changes in the amount of liver
lipids were insignificant.
Discussion
Our study conclusively showed that short-term courses
of probiotic mixtures from birth have a preventive effect
on fatty liver disease development under condition of
the MSG-induced obesity. Nevertheless therapeutic po-
tential are more pronounced for alive probiotic multi-
strain mixture (VII) because only for Symbiter group
significantly lower degree of steatosis and total NAS
score were detected as compared to monocomponent
probiotics groups (III–V) and any significant changes in
liver histology assessment parameters were not found
compared with intact rats.
In particular, different Lactobacillus та Bifidobacter-
ium strains have specific effects on the markers of
obesity in rodent models. The analysis of from the lit-
erature data published from January 2013 to July
2014 by Cani et al. showed that at least 15 different
strains of Lactobacillus and 3 strains of Bifidobacterium
do not equally influence hepatic lipids and NAFLD devel-
opment in different animal models. Remarkably, 12 strains
decreased hepatic tissue inflammation and 11 reduced the
hepatic triglyceride content when given as a single
treatment [22].
In contrast to our study, where we did not notice
any significant single-strain specific changes in lipid
metabolism and NAFLD development, a recent study
compared the effects of four Bifidobacteria strains
(Bifidobacteria L66-5, L75-4, M13-4 and FS31-12) on
lipid metabolism in an high-fat diet obese mice. All
Fig. 3 Light microscopic micrographs of the rat liver tissue stained
with hematoxylin and eosin, ×400. In micrographs focal mild
microvesicular steatosis were mainly observed. a - Poliprobiotics
group; b - Symbiter group
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the four strains could reduce serum and liver trigly-
ceride and significantly alleviate the lipid deposition
in the liver. As for total cholesterol only Bifidobac-
teria L66-5 and Bifidobacteria FS31-12 significantly
decreased its amount in the liver [23].
Administration of single-strain probiotic of Lactobacil-
lus rhamnosus GG protects mice from NAFLD develop-
ment induced by a high-fructose diet through an
increase of beneficial bacteria, restoration of the gut bar-
rier function and subsequent attenuation of liver inflam-
mation and steatosis [24]. Another study demonstrated
that treatment with Lactobacillus rhamnosus GG for
13 weeks under condition of high fat diet improved in-
sulin sensitivity and reduced lipid accumulation by
stimulating adiponectin secretion and consequent activa-
tion of AMPK [25].
In addition, it was reported that an oral supplementa-
tion of Bifidobacterium adolescentis (5 × 10(7) CFU/ml)
ad libitum for 12 weeks protected against a diet-
induced NASH in C57BL/6 mice. Furthermore, mice
treated with probiotic had significantly decreased liver
damage, which was associated with prevention from
lipid peroxidation, NFκB activation and finally inflam-
mation in the liver [26].
On the other hand, our data find support in another
recent study that established that single-strain probiotics
of Lactobacillus curvatus HY7601 significantly reduced
liver fat accumulation as compared to Lactobacillus
plantarum KY1032 in diet-induced obesity. Combination
of this probiotic was more effective for inhibiting gene
expressions of various enzymes responsible for fatty acid
synthesis in the liver, concomitant with decreases in fatty
acid oxidation-related enzyme activities and their gene
expressions [27].
Plaza-Diaz in Zucker rats with genetic determined
obesity evaluated the effects of Lactobacillus paracasei
CNCM I-4034, Bifidobacterium breve CNCM I-4035 and
Lactobacillus rhamnosus CNCM I-4036 probiotic strains
and their mixture on the hepatic steatosis development
as compared to placebo. In this study only single-strain
probiotic of Lactobacillus rhamnosus or Bifidobacterium
breve and the mixture of Bifidobacterium breve and
Lactobacillus paracasei decreased triacylglycerol content
in the rat liver and reduced manifestation of hepatic
steatosis in part by lowering serum LPS [28].
The improvement of NAFLD by probiotics strains can
be achieved by various pathways. Mei et al. (2015) have
shown that decrease in triglycerides level, total choles-
terol, free fatty acids, and cholesterol low-density
lipoproteins is associated with an increased uptake of
cholesterol from the blood, its excretion with bile by the
liver, and reduction of cholesterol synthesis under condi-
tions of probiotic treatment of NAFLD [29]. Contrary to
our findings, the scientists established the effectiveness
of monostrains of Lactobacillus species. The influence of
probiotics on lipid metabolism was associated with up-
and downregulation of certain genes. The team has
found an overexpression of low-density lipoproteins re-
ceptor that enhances the absorption of low-density lipo-
proteins by the liver. Besides, cholesterol 7α-hydroxylase
Fig. 4 Light microscopic micrographs of the rat liver tissue stained with hematoxylin and eosin, ×400. In micrographs microvesicular steatosis
with perivascular leukocyte infiltration at zone 3 (mild lobular inflammation) (c, d) and focal necrosis as a result of hepatocytes ballooning
degeneration – lack of nuclei (in center) (a, b) was observed. a - MSG-induced obesity group; b - B. animalis VKL group; c - B. animalis VKB group;
d - L. casei IMVB-7280 group
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activity was elevated that proves the enhanced excretion
of cholesterol with bile. Moreover, the farnesoid X re-
ceptor was up-regulated indicating the increased bile
acid production. The reduction of cholesterol synthesis
by probiotics was confirmed by the downregulation of 3-
hydroxy-3-methyl glutaryl coenzyme A reductase and
sterol regulatory element binding protein-1c. In addition,
PPAR-α expression was high and PPAR-γ was low in
rats with NAFLD and treated with probiotic strains
that diverts lipid metabolism from fat deposition to
β-oxidation of fatty acids [29].
Some light on the underlying mechanisms of probiotic
impact was shed. It is known that symbiotic bacteria
can produce short chain fatty acids, e.g. butyrate. This
substance inhibits the activation of toll-like receptor
(TLR)-dependent signalling cascades in the liver
through strengthening gut tight junction, and reduc-
tion of bacterial endotoxin translocation to the liver
that was shown on the model of western-style diet-
induced NAFLD [30]. It was established that butyrate
prevented lipid peroxidation through the reduction of
4-hydroxynonenal protein adducts level and downre-
gulates inducible nitric oxide synthase that is critical
for regulation not only NF-κB-depending signalling
cascades in the development of NAFLD but also for
expression of the TLR-4 adaptor protein myeloid differen-
tiation primary response gene 88. Thus, production of
butyrate results in attenuation of inflammation and TLR-
dependent signalling in the liver under conditions of
experimental NAFLD [30].
Fig. 5 Liver total lipids (a) and triglycerides (b) content of rats with the MSG-induced obesity and probiotic correction. Data are presented as the
M ± SEM. One-way ANOVA with post hoc Tukeys test for multiple comparisons were performed for data analysis. a, b Values at the same row with
different superscript letters show significant differences at p < 0.05
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Conclusions
Postnatal administration of both alive (VII) and lyophi-
lized (VI) probiotic mixture lead to significant decrease
of hepatic steatosis, total lipids and triglycerides content
in the liver as compared to MSG-obesity and may be
more beneficial than single-strain probiotics. Thus, mul-
ticomponent probiotics have a preventive effect on fatty
liver disease development. It may be related to more
pronounced viability of the alive strains and their pre-
vention of bacterial translocation. Multistrain or multi-
species formed mutualistic interactions in mixtures and
therefore were able to share with different metabolites,
affect different receptors and produced various biologic-
ally active compounds. So, their synergistic overall effect
is greater than the sum of their individual effects. On
the other hand, most likely due to different putative
mechanisms of action, strain-specific probiotics must be
considered for novel investigation in different metabolic
diseases.
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